Placeholder

Asenapine Maleate

CAS No:
85650-56-2 Categories: , ,
  • # LGM Pharma is a Asenapine Maleate CAS# 85650-56-2 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Asenapine Maleate
  • CAS #: 85650-56-2
  • IUPAC: (3aR*, 12bR*)-5-Chloro-2, 3, 3a, 12b-tetrahydro-2-methyl-1H-dibenz[2, 3:6, 7]oxepino[4, 5-c]pyrrole maleate
  • Formula: C17H16CINO.C4H4O4
  • Molecular Mass: 401.84
  • General Reference:

    Marston et al (2009) Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacol. 206 699.

    Meltzer et al (2009) Asenapine. Nat.Rev.Drug Discov. 8 843. PMID: 19876039.

    Shahid et al (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J.Psychopharmacol. 23 65. PMID: 18308814.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. We’re working to update our website to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

Click here to read our press release
This website uses cookies. By using our site, you agree to our terms of service